SAHPRA Biosimilars Approval: Pathway Analysis & Access Impact
This article analyzes SAHPRA's biosimilars approval pathway and its significant impact on improving access to vital treatments, including adalimumab.
Quick Answer
This article analyzes SAHPRA's biosimilars approval pathway and its significant impact on improving access to vital treatments, including adalimumab.
Key Questions
- How long does SAHPRA take to approve a biosimilar?
- What is SAHPRA's pre-submission scientific advice program?
- How does SAHPRA define biosimilar interchangeability?
- What impact do biosimilars have on medicine prices in South Africa?
- How does SAHPRA align with international biosimilar standards?
The South African Health Products Regulatory Authority (SAHPRA) operates a structured biosimilar approval pathway that delivers regulatory decisions within 240 calendar days. This framework balances rigorous safety standards with timely patient access, supporting South Africa's National Health Insurance objectives by enabling affordable biologic therapies for autoimmune diseases, cancer, and diabetes.
Contents8 sections
Key Takeaways
- 240-day approval timeline: SAHPRA's biosimilar pathway typically concludes within 240 calendar days, including pre-submission advice, clinical trial review (under 70 days), dossier validation (15 days), and scientific assessment (approximately 60 days). Source: SAHPRA Guidelines
- WHO-aligned framework: SAHPRA incorporates WHO guidelines on biosimilar evaluation, requiring comprehensive quality, non-clinical, and clinical comparability studies to demonstrate similarity to reference biologics. Source: WHO Technical Report
- Proven price competition: The South Africa Competition Commission documented that biosimilars consistently enter at lower prices than originators, with second entrants driving further reductions—directly improving patient access to essential medicines. Source: CompCom Working Paper CC2024/02
- Pre-submission engagement: SAHPRA offers face-to-face scientific advice meetings that help applicants optimize development strategy, comparability study design, and dossier structure before formal submission. Source: SAHPRA Clinical Trials
What Is SAHPRA's Role in Biosimilar Regulation?
The South African Health Products Regulatory Authority (SAHPRA) serves as the national regulatory authority for medicines and medical devices under the Medicines and Related Substances Act 101 of 1965. The authority ensures all pharmaceutical products meet standards for safety, quality, and efficacy before entering the South African market.
Biosimilars—biologic medicines highly similar to already-approved reference biologics with no clinically meaningful differences in safety or efficacy—represent a key mechanism for expanding access to expensive biologic therapies. Unlike generic drugs, which are identical copies of small-molecule medicines, biosimilars are produced in living cells and require thorough comparability studies to demonstrate similarity. Learn more about biosimilars.
In South Africa, biosimilars address a pressing healthcare need. The high cost of reference biologics often limits patient access to treatments for rheumatoid arthritis, inflammatory bowel disease, cancer, and diabetes. SAHPRA's structured approval pathway reflects a deliberate policy commitment to support both regulatory rigor and healthcare access objectives within the National Health Insurance (NHI) framework.
How Does the SAHPRA Biosimilar Approval Process Work?
SAHPRA's biosimilar approval pathway consists of sequential, clearly defined phases. Each phase carries specific timelines and regulatory requirements designed to ensure thorough evaluation while maintaining efficiency.
| Phase | Timeline | Key Activities |
|---|---|---|
| Pre-submission scientific advice | Variable | Face-to-face meetings; development strategy guidance; comparability study design consultation |
| Clinical trial application (CTA) | Under 70 days | Assessment of comparative clinical study protocols; safety and ethical review |
| Dossier validation | 15 days | Administrative completeness check; confirmation of required documentation |
| Queuing | Under 28 days | Workload management; reviewer allocation; resource planning |
| Scientific review | Approximately 60 days | External expert assessment of comparability data; quality, non-clinical, and clinical evaluation |
| GMP certification | Variable | Manufacturing facility inspection; quality system verification |
| Total timeline | 240 days (cumulative) | Submission to final approval decision |
Pre-submission scientific advice offers applicants the opportunity to engage directly with SAHPRA regulators before formal submission. These face-to-face meetings address biosimilar development strategy, comparability study design, clinical trial protocols, and dossier structure. Early engagement reduces the risk of deficiencies during formal review and improves submission quality.
Clinical trial application review assesses proposed comparative clinical studies for feasibility, safety, and ethical appropriateness. SAHPRA aims to complete this review within 70 days, enabling timely trial initiation for biosimilars requiring local clinical data.
Scientific review represents the core assessment phase. External expert assessors evaluate analytical comparability data, animal toxicology studies, clinical pharmacology data, and comparative efficacy and safety results. This phase determines whether the biosimilar meets SAHPRA's standards for similarity to the reference product.
What Evidence Does SAHPRA Require for Biosimilar Approval?
SAHPRA's evidence requirements align with WHO guidelines on evaluation of biosimilars and incorporate principles from the EMA's centralised procedure. The framework emphasizes a stepwise approach to comparability testing.
Quality data requirements include comprehensive physicochemical and biological characterization. Applicants must demonstrate that the biosimilar has a quality profile highly similar to the reference product through analytical studies covering:
- Primary and higher-order structure analysis
- Post-translational modifications (glycosylation, phosphorylation)
- Biological activity and potency assays
- Purity and impurity profiles
- Stability data under various conditions
Non-clinical requirements involve in vitro functional assays and, when necessary, in vivo animal studies. The SAHPRA Biosimilars Guidance Document specifies that animal studies may be waived if in vitro assays provide sufficient comparative data on biological activity, toxicity, and pharmacokinetic behavior.
Clinical requirements focus on demonstrating pharmacokinetic (PK) and pharmacodynamic (PD) similarity through comparative studies in sensitive populations. For monoclonal antibodies and other complex biologics, SAHPRA typically requires:
- Comparative PK studies in healthy volunteers or patients
- PD marker assessments where relevant
- Confirmatory efficacy trials in the most sensitive indication
- Comprehensive immunogenicity evaluation
- Safety data from all comparative studies
How Do Biosimilars Improve Medicine Access in South Africa?
The South Africa Competition Commission's 2024 working paper on the competitive environment for biosimilars provides strong evidence of market impact. The study analyzed pricing and entry patterns for biosimilars registered in South Africa, including infliximab, rituximab, and trastuzumab products.
Price competition effects: The research documented consistent price reductions following biosimilar entry. First-entry biosimilars typically launch below the originator price. When a second biosimilar enters, further competition drives prices lower. This pattern benefits patients, healthcare budgets, and the National Health Insurance system.
Registered products: While South Africa has fewer registered biosimilars than some developed markets, the regulatory pathway continues to attract applications. Registered products include biosimilars of infliximab (REMSIMA, among others), rituximab, and trastuzumab, expanding treatment options for autoimmune diseases and cancer.
Healthcare system support: South Africa's NHI framework aims to expand universal health coverage while controlling costs. Biosimilar availability directly supports these objectives by making biologic therapies accessible within public healthcare budgets. The SAHPRA approval pathway operationalizes this policy priority through efficient regulatory review.
What Is the African Medicines Agency and How Will It Affect SAHPRA?
The African Medicines Agency (AMA) became operational in 2024 as a specialized agency of the African Union. The AMA aims to harmonize medicine regulation across member states and strengthen regulatory capacity continent-wide.
Research published in Health Science Reports (2024) outlines the AMA's potential impact on national regulators like SAHPRA. The agency's establishment creates opportunities for regulatory harmonization, mutual recognition procedures, and shared technical expertise. For biosimilar developers, future AMA alignment could streamline multi-country registration across African markets.
SAHPRA's current framework already incorporates international best practices from WHO and EMA guidelines. This positions the authority well for future AMA harmonization efforts. Stakeholders should monitor AMA guideline development, particularly for biosimilar-specific recommendations that may influence SAHPRA's existing requirements.
Frequently Asked Questions
How long does SAHPRA take to approve a biosimilar?
SAHPRA's biosimilar approval process typically concludes within 240 calendar days from submission to final decision. This timeline includes pre-submission scientific advice, clinical trial application review (under 70 days), dossier validation (15 days), queuing (under 28 days), scientific review (approximately 60 days), GMP certification, and final approval.
What is SAHPRA's pre-submission scientific advice program?
SAHPRA offers pre-submission scientific advice through face-to-face meetings with biosimilar applicants. This early engagement allows developers to obtain regulatory guidance on biosimilar development strategy, comparability study design, clinical trial protocols, and dossier structure. The program helps optimize submission quality and reduces the likelihood of deficiencies during formal review.
How does SAHPRA define biosimilar interchangeability?
According to SAHPRA's guidelines, interchangeability refers to the medical practice of switching between the reference biologic and its biosimilar, or between different biosimilars of the same reference product. SAHPRA requires thorough evidence of comparable safety and efficacy, including switching studies, before granting interchangeability status. The decision ultimately rests with the prescribing physician based on individual patient needs.
What impact do biosimilars have on medicine prices in South Africa?
Research by the South Africa Competition Commission shows that biosimilars enter the market at lower prices than reference biologics. When a second biosimilar enters, further price competition occurs between biosimilars. The first biosimilar typically enters at a price below the originator, and the second biosimilar enters at an even lower price, directly benefiting patients through improved access to essential biologic therapies.
How does SAHPRA align with international biosimilar standards?
SAHPRA's biosimilar approval framework aligns with WHO guidelines on evaluation of biosimilars and incorporates principles from the EMA's centralised procedure. The authority requires comprehensive comparability studies covering quality, non-clinical, and clinical domains. This alignment supports future harmonization with the African Medicines Agency and facilitates mutual recognition discussions with other regulatory authorities.
Primary Sources
- South African Health Products Regulatory Authority (SAHPRA). Biosimilar Medicine Quality, Non-clinical and Clinical Requirements. Document SAHPGL-PEM-BIO-02, Version 2, Updated 15 December 2025. https://www.sahpra.org.za/document/biosimilar-medicine-quality-non-clinical-and-clinical-requirements/
- South African Health Products Regulatory Authority (SAHPRA). Clinical Trials. SAHPRA Clinical Trial Unit Guidelines. https://www.sahpra.org.za/clinical-trials/
- World Health Organization. Guidelines on Evaluation of Biosimilars. WHO Technical Report Series, Annex 3, adopted 4–8 April 2022. https://cdn.who.int/media/docs/default-source/biologicals/annex-3---who-guidelines-on-evaluation-of-biosimilars---sj-ik-5-may-2022.pdf
- European Medicines Agency. Procedural Advice for Users of the Centralised Procedure for Similar Biological Medicinal Products Applications. EMA/940451/2011. https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/
- South Africa Competition Commission. Competitive Landscape of Biosimilars in South Africa. Working Paper CC2024/02, October 2024. Authors: Melissa Naidoo, Tankiso Thibane, Phakamani Tunyiswa. https://www.compcom.co.za/wp-content/uploads/2024/10/CC202402...
- Abdulwahab AO, Okafor UG, Adesuyi DS, et al. The African Medicines Agency and Medicines Regulation: Progress, challenges, and recommendations. Health Science Reports. 2024;7:e117. https://researchonline.lshtm.ac.uk/id/eprint/4681671/
Continue Exploring
Jump into the entities behind this story.
This article follows our editorial standards. Report a correction via editorial contact.
Continue Your Research
Industry Reports & Whitepapers
- Comparative Analysis of FDA and EMA Drug Approval Processes — This study compares FDA and EMA drug approval processes, highlighting key differences and implicatio…